Suppr超能文献

鞘内输注系统用于慢性非癌性疼痛长期管理的系统评价

Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain.

作者信息

Patel Vikram B, Manchikanti Laxmaiah, Singh Vijay, Schultz David M, Hayek Salim M, Smith Howard S

机构信息

ACMI Pain Care, Algonquin, IL 60102, USA.

出版信息

Pain Physician. 2009 Mar-Apr;12(2):345-60.

Abstract

BACKGROUND

Disability, societal, and health impact of chronic intractable pain secondary to various failed therapies is a major issue. As advanced therapy, implantable therapies, which include intrathecal devices and spinal cord stimulation systems, are frequently used in managing chronic intractable pain. Thus, continuous infusion of intrathecal medication is one of the methods used for the control of chronic, refractory, cancer, and non-cancer pain. However, despite the high costs of chronic non-cancer pain, it has been claimed that there is a lack of evidence for intrathecal infusion systems and the cost effectiveness of these systems has been questioned in improving pain and function.

STUDY DESIGN

A systematic review of intrathecal infusion devices for chronic non-cancer pain.

OBJECTIVE

To determine the efficacy, utilization, safety, and complications associated with the use of intrathecal infusion devices for long-term management of chronic non-cancer pain.

METHODS

Literature search was performed through EMBASE, Medline, Cochrane databases, and systematic reviews identified from 1966 to December 2008. Studies were then reviewed and assessed using the Agency for Healthcare Research and Quality (AHRQ) criteria for observational studies and the Cochrane Musculoskeletal Review Group criteria for randomized trials. The level of evidence was determined using 5 levels of evidence, ranging from Level I to III with 3 subcategories in Level II, based on the quality of evidence developed by the U.S. Preventive Services Task Force (USPSTF).

OUTCOME MEASURES

The primary outcome measure was pain relief (short-term relief < or = one-year and long-term > one-year). Secondary outcome measures of improvement in functional status, psychological status, return to work, and reduction in opioid intake were also utilized.

RESULTS

The level of evidence for intrathecal infusion systems indicated either Level II-3 or Level III (limited) based on U.S. Preventive Services Task Force (USPSTF) criteria.

LIMITATIONS

The limitations of this study include the paucity of literature, lack of quality evidence, and lack of randomized trials.

CONCLUSION

This systematic review illustrates Level II-3 or Level III (limited) evidence for intrathecal infusion systems for long-term relief in chronic non-cancer pain.

摘要

背景

各种治疗失败后继发的慢性顽固性疼痛对残疾、社会和健康造成的影响是一个重大问题。作为先进的治疗方法,包括鞘内给药装置和脊髓刺激系统在内的植入式治疗方法常用于管理慢性顽固性疼痛。因此,鞘内持续输注药物是控制慢性、难治性、癌症和非癌症疼痛的方法之一。然而,尽管慢性非癌性疼痛治疗成本高昂,但有人声称缺乏关于鞘内输注系统的证据,且这些系统在改善疼痛和功能方面的成本效益受到质疑。

研究设计

对用于慢性非癌性疼痛的鞘内输注装置进行系统评价。

目的

确定与使用鞘内输注装置长期管理慢性非癌性疼痛相关的疗效、利用率、安全性和并发症。

方法

通过EMBASE、Medline、Cochrane数据库进行文献检索,并检索1966年至2008年12月期间的系统评价。然后根据医疗保健研究与质量机构(AHRQ)的观察性研究标准和Cochrane肌肉骨骼审查小组的随机试验标准对研究进行审查和评估。根据美国预防服务工作组(USPSTF)制定的证据质量,使用从I级到III级共5个证据级别来确定证据水平,其中II级又分为3个亚类。

结果指标

主要结果指标是疼痛缓解(短期缓解≤1年,长期缓解>1年)。还采用了功能状态改善、心理状态改善、重返工作岗位和阿片类药物摄入量减少等次要结果指标。

结果

根据美国预防服务工作组(USPSTF)标准,鞘内输注系统的证据水平为II-3级或III级(有限)。

局限性

本研究的局限性包括文献匮乏、缺乏高质量证据以及缺乏随机试验。

结论

本系统评价表明,鞘内输注系统在长期缓解慢性非癌性疼痛方面的证据为II-3级或III级(有限)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验